PAQ Therapeutics to Present First Clinical Data for PT0253
The late-breaking oral presentation will highlight PT0253’s initial safety profile and antitumor activity in advanced so…
The late-breaking oral presentation will highlight PT0253’s initial safety profile and antitumor activity in advanced so…